Disease Overview：Multiple Myeloma（MM）
Multiple Myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells within the bone marrow, leading to end-organ damage—including hypercalcemia, renal insufficiency, anemia, and lytic bone lesions (CRAB criteria). It accounts for approximately 10% of all hematologic cancers and predominantly affects older adults, with median diagnosis age around 69 years. Disease progression is driven by genetic abnormalities (e.g., del(17p), t(4;14), gain(1q)), dysregulated cytokine signaling (notably IL-6 and BAFF), and bone marrow microenvironment interactions. Diagnosis relies on serum/urine protein electrophoresis, immunofixation, free light chain assay, bone marrow biopsy with flow cytometry and cytogenetics, and advanced imaging such as whole-body low-dose CT or PET/CT to assess skeletal involvement. Treatment paradigms have evolved significantly, incorporating proteasome inhibitors (bortezomib, carfilzomib), immunomodulatory drugs (lenalidomide, pomalidomide), monoclonal antibodies (daratumumab, isatuximab), and emerging BCMA-targeted therapies including bispecific T-cell engagers and CAR-T cell products.
China offers compelling advantages for MM management: Tier-1 hospitals—such as Peking Union Medical College Hospital, Ruijin Hospital (Shanghai Jiao Tong University), and Sun Yat-sen University Cancer Center—host internationally trained hematologists with extensive experience in risk-adapted therapy, minimal residual disease (MRD)-guided treatment escalation/de-escalation, and access to FDA- and NMPA-approved novel agents, including domestically developed BCMA CAR-T therapies (e.g., Equecabtagene Autoleucel). State-of-the-art infrastructure includes next-generation sequencing platforms, automated MRD detection via next-generation flow (NGF), and integrated multidisciplinary tumor boards. Clinical outcomes align closely with global benchmarks: five-year overall survival exceeds 60% in newly diagnosed transplant-eligible patients, with growing real-world evidence supporting durable responses in relapsed/refractory settings. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising protocol fidelity or supportive care standards—making high-intensity regimens, autologous stem cell transplantation, and even cellular therapies more accessible.
As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying physician credentials, coordinating appointments at accredited centers, providing itemized, transparent cost estimates pre-arrival, arranging visa support, medical translation, accommodation, and post-treatment follow-up coordination—all tailored to individual clinical needs and cultural preferences.
Multiple Myeloma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Multiple Myeloma (Hematology/Oncology)
Non-Surgical/Medical Therapy (First-Line & Maintenance)
*Eligibility*: Newly diagnosed, relapsed/refractory, or transplant-ineligible patients; requires confirmed monoclonal protein, bone marrow plasma cell ≥10%, and end-organ damage (CRAB criteria).
- •Induction Therapy (3–4 cycles)
- *VRd regimen (Bortezomib + Lenalidomide + Dexamethasone)*: ¥42,000–¥54,000/cycle → $5,820–$7,500 - *Daratumumab-based (e.g., D-Rd)*: ¥68,000–¥82,000/cycle → $9,430–$11,370
- •Supportive Care & Monitoring
- Quantitative immunoglobulins + SPEP + UPEP: ¥480 → $67 - Bone marrow biopsy with flow cytometry & FISH: ¥2,100 → $291 - Whole-body low-dose CT or PET/CT (per scan): ¥3,800–¥5,200 → $527–$721
Surgical/Procedural Interventions
*Eligibility*: Symptomatic spinal cord compression, pathologic vertebral fracture unresponsive to radiotherapy, or impending limb-threatening bone lesion. Performed by Orthopedic Oncology or Interventional Radiology.
- •Vertebroplasty/Kyphoplasty (per level): ¥18,000–¥24,500 → $2,500–$3,400
- •Stabilization Surgery (spinal fusion, tumor resection): ¥65,000–¥92,000 → $9,010–$12,750
- •*Preoperative Workup (mandatory)*: CBC, renal panel, coagulation, ECG, chest X-ray, MRI spine: ¥1,950 → $270
Special/Complex Condition Management
- •Autologous Stem Cell Transplant (ASCT): Eligible for fit patients <70 years with adequate organ function.
- Apheresis + cryopreservation: ¥8,200 → $1,140 - High-dose Melphalan conditioning + inpatient care (14–21 days): ¥48,000–¥63,000 → $6,650–$8,730
- •CAR-T Therapy (Cilta-cel or BCMA-targeted): Approved for ≥4 prior lines; requires lymphodepletion.
Quick Selection Guide
- •<65 years, fit, no major comorbidities: VRd induction → ASCT → Lenalidomide maintenance. *Total estimated first-year cost: $32,000–$41,000*.
- •65–75 years, moderate renal impairment: Rd or Daratumumab-Rd. Avoid ASCT; prioritize renal-sparing regimens. *Annual cost: $18,000–$26,000*.
- •>75 years or frail (ADL-dependent, eGFR <30 mL/min): Once-weekly low-dose Rd or Daratumumab monotherapy. Minimize toxicity; emphasize supportive care. *Annual cost: $12,000–$19,000*.
- •Relapsed/refractory after ≥3 lines: CAR-T if accessible and lymphocyte count ≥100/μL; otherwise, Selinexor + Bortezomib + Dexamethasone (¥31,000/cycle → $4,300).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Multiple Myeloma Medical Vacation Packages
Curated transparent all-inclusive packages combining Multiple Myeloma treatment with China top medical destinations:
